Lyduine Collij, PhD, BioFINDER group, Lund University, Lund, Sweden, shares an overview of the latest research questions regarding amyloid-PET imaging for early diagnosis and detection. Despite the growing role of fluid biomarkers in Alzheimer’s disease screening and monitoring, PET imaging remains critical due to its unmatched accuracy, research utility, and unique ability to provide regional information. There is substantial interest in establishing optimal inclusion criteria based on amyloid PET imaging. Looking beyond binary cut offs for positivity and negativity may be important to gain a better understanding of the impact of pathology severity on treatment efficacy. Use of amyloid-PET quantification methods is growing both clinically and in the research domain. Additionally, research teams are looking into different patterns of amyloid accumulation, assessing the clinical utility of deeper stratification. This interview took place at the CTAD 2023 conference in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
